These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27246553)

  • 1. Quantitative proteome profiling of dystrophic dog skeletal muscle reveals a stabilized muscular architecture and protection against oxidative stress after systemic delivery of MuStem cells.
    Lardenois A; Jagot S; Lagarrigue M; Guével B; Ledevin M; Larcher T; Dubreil L; Pineau C; Rouger K; Guével L
    Proteomics; 2016 Jul; 16(14):2028-42. PubMed ID: 27246553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
    Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
    BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Gene Expression Profiling of Dystrophic Dog Muscle after MuStem Cell Transplantation.
    Robriquet F; Lardenois A; Babarit C; Larcher T; Dubreil L; Leroux I; Zuber C; Ledevin M; Deschamps JY; Fromes Y; Cherel Y; Guevel L; Rouger K
    PLoS One; 2015; 10(5):e0123336. PubMed ID: 25955839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs.
    Rouger K; Larcher T; Dubreil L; Deschamps JY; Le Guiner C; Jouvion G; Delorme B; Lieubeau B; Carlus M; Fornasari B; Theret M; Orlando P; Ledevin M; Zuber C; Leroux I; Deleau S; Guigand L; Testault I; Le Rumeur E; Fiszman M; Chérel Y
    Am J Pathol; 2011 Nov; 179(5):2501-18. PubMed ID: 21924229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular Delivery of Allogeneic MuStem Cells in Dystrophic Dogs Requires Only Short-Term Immunosuppression to Avoid Host Immunity and Generate Clinical/Tissue Benefits.
    Lorant J; Larcher T; Jaulin N; Hedan B; Lardenois A; Leroux I; Dubreil L; Ledevin M; Goubin H; Moullec S; Deschamps JY; Thorin C; André C; Adjali O; Rouger K
    Cell Transplant; 2018 Jul; 27(7):1096-1110. PubMed ID: 29871519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: Local or systemic?
    Kerkis I; Ambrosio CE; Kerkis A; Martins DS; Zucconi E; Fonseca SA; Cabral RM; Maranduba CM; Gaiad TP; Morini AC; Vieira NM; Brolio MP; Sant'Anna OA; Miglino MA; Zatz M
    J Transl Med; 2008 Jul; 6():35. PubMed ID: 18598348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy.
    Terrill JR; Duong MN; Turner R; Le Guiner C; Boyatzis A; Kettle AJ; Grounds MD; Arthur PG
    Redox Biol; 2016 Oct; 9():276-286. PubMed ID: 27611888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative proteomic analysis of dystrophic dog muscle.
    Guevel L; Lavoie JR; Perez-Iratxeta C; Rouger K; Dubreil L; Feron M; Talon S; Brand M; Megeney LA
    J Proteome Res; 2011 May; 10(5):2465-78. PubMed ID: 21410286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs.
    Sitzia C; Farini A; Jardim L; Razini P; Belicchi M; Cassinelli L; Villa C; Erratico S; Parolini D; Bella P; da Silva Bizario JC; Garcia L; Dias-Baruffi M; Meregalli M; Torrente Y
    Mol Ther; 2016 Nov; 24(11):1949-1964. PubMed ID: 27506452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splitting of Pi and other ³¹P NMR anomalies of skeletal muscle metabolites in canine muscular dystrophy.
    Wary C; Naulet T; Thibaud JL; Monnet A; Blot S; Carlier PG
    NMR Biomed; 2012 Oct; 25(10):1160-9. PubMed ID: 22354667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy.
    Bish LT; Sleeper MM; Forbes SC; Morine KJ; Reynolds C; Singletary GE; Trafny D; Pham J; Bogan J; Kornegay JN; Vandenborne K; Walter GA; Sweeney HL
    Hum Gene Ther; 2011 Dec; 22(12):1499-509. PubMed ID: 21787232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ringo: discordance between the molecular and clinical manifestation in a golden retriever muscular dystrophy dog.
    Zucconi E; Valadares MC; Vieira NM; Bueno CR; Secco M; Jazedje T; da Silva HC; Vainzof M; Zatz M
    Neuromuscul Disord; 2010 Jan; 20(1):64-70. PubMed ID: 19944604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive muscle proteome changes in a clinically relevant pig model of Duchenne muscular dystrophy.
    Fröhlich T; Kemter E; Flenkenthaler F; Klymiuk N; Otte KA; Blutke A; Krause S; Walter MC; Wanke R; Wolf E; Arnold GJ
    Sci Rep; 2016 Sep; 6():33362. PubMed ID: 27634466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models.
    Quenneville SP; Chapdelaine P; Skuk D; Paradis M; Goulet M; Rousseau J; Xiao X; Garcia L; Tremblay JP
    Mol Ther; 2007 Feb; 15(2):431-8. PubMed ID: 17235323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal Muscle Regenerative Potential of Human MuStem Cells following Transplantation into Injured Mice Muscle.
    Lorant J; Saury C; Schleder C; Robriquet F; Lieubeau B; Négroni E; Leroux I; Chabrand L; Viau S; Babarit C; Ledevin M; Dubreil L; Hamel A; Magot A; Thorin C; Guevel L; Delorme B; Péréon Y; Butler-Browne G; Mouly V; Rouger K
    Mol Ther; 2018 Feb; 26(2):618-633. PubMed ID: 29221805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose Metabolism as a Pre-clinical Biomarker for the Golden Retriever Model of Duchenne Muscular Dystrophy.
    Schneider SM; Sridhar V; Bettis AK; Heath-Barnett H; Balog-Alvarez CJ; Guo LJ; Johnson R; Jaques S; Vitha S; Glowcwski AC; Kornegay JN; Nghiem PP
    Mol Imaging Biol; 2018 Oct; 20(5):780-788. PubMed ID: 29508262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the six-minute walk test to characterize golden retriever muscular dystrophy.
    Acosta AR; Van Wie E; Stoughton WB; Bettis AK; Barnett HH; LaBrie NR; Balog-Alvarez CJ; Nghiem PP; Cummings KJ; Kornegay JN
    Neuromuscul Disord; 2016 Dec; 26(12):865-872. PubMed ID: 27818009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRMD cardiac and skeletal muscle metabolism gene profiles are distinct.
    Markham LW; Brinkmeyer-Langford CL; Soslow JH; Gupte M; Sawyer DB; Kornegay JN; Galindo CL
    BMC Med Genomics; 2017 Apr; 10(1):21. PubMed ID: 28390424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of cardiac progenitor cell potency in GRMD dogs.
    Cassano M; Berardi E; Crippa S; Toelen J; Barthelemy I; Micheletti R; Chuah M; Vandendriessche T; Debyser Z; Blot S; Sampaolesi M
    Cell Transplant; 2012; 21(9):1945-67. PubMed ID: 22513051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.